Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Cancers|July 24, 2021
A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck CancerMarkus Hecht, Dennis Hahn, Philipp Wolber, et al.
BMC Cancer|September 30, 2020
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancerMarkus Hecht, Dennis Hahn, Philipp Wolber, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 12, 2020
Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trialRainer Fietkau, Markus Hecht, Benjamin Hofner, et al.
Annals of Nuclear Medicine|May 9, 2022
F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trialM Beck, J Hartwich, M Eckstein, et al.
Medcomm|January 16, 2026
Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaJian-Guo Zhou, Markus Eckstein, Haitao Wang, et al.
Neoplasia (New York, N.Y.)|January 17, 2024
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma - knowledge obtained from the CheckRad-CD8 trialMarkus Hecht, Benjamin Frey, Udo S Gaipl, et al.
Journal for Immunotherapy of Cancer|October 7, 2020
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, et al.
Journal for Immunotherapy of Cancer|January 26, 2022
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancerMarkus Hecht, Markus Eckstein, Sandra Rutzner, et al.
Frontiers in Oncology|September 3, 2024
De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a prospective multicenter phase II trial (DIREKHT Trial)Marlen Haderlein, Jens von der Grün, Panagiotis Balermpas, et al.
Frontiers in Oncology|April 7, 2023
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trialSusanne Wiegand, Gunnar Wichmann, Jeannette Vogt, et al.
Pageof 9